keyword
MENU ▼
Read by QxMD icon Read
search

Recurrence-free survival

keyword
https://www.readbyqxmd.com/read/29655662/evaluation-of-low-intensity-anti-coagulation-with-a-fully-magnetically-levitated-centrifugal-flow-circulatory-pump-the-magentum-1-study
#1
Ivan Netuka, Peter Ivák, Zuzana Tučanová, Stanislav Gregor, Ondrej Szárszoi, Poornima Sood, Daniel Crandall, Jessica Rimsans, Jean Marie Connors, Mandeep R Mehra
BACKGROUND: The HeartMate 3 left ventricular assist system is engineered to avoid pump thrombosis, yet bleeding complications persist. We investigated the safety of low-intensity anti-coagulation in patients with the HeartMate 3. METHODS: The Minimal AnticoaGulation EvaluatioNTo aUgment heMocompatibility (MAGENTUM 1) pilot study is a prospective, single-arm study of low-intensity warfarin anti-coagulation in patients implanted with the HeartMate 3 pump. After standard warfarin anti-coagulation (international normalized ratio [INR] 2...
March 27, 2018: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/29652232/long-term-tumor-control-following-stereotactic-radiosurgery-for-jugular-paraganglioma-using-3d-volumetric-segmentation
#2
Neil S Patel, Matthew L Carlson, Bruce E Pollock, Colin L W Driscoll, Brian A Neff, Robert L Foote, Christine M Lohse, Michael J Link
OBJECTIVE The morbidity of gross-total resection of jugular paraganglioma (JP) is often unacceptable due to the potential for irreversible lower cranial neuropathy. Stereotactic radiosurgery (SRS) has been used at the authors' institution since 1990 for the treatment of JP and other benign intracranial tumors. Conventional means of assessing tumor progression using linear measurements or elliptical approximations are imprecise due to the irregular shape and insinuating growth pattern of JP. The objective of this study was to assess long-term tumor control in these patients by using slice-by-slice 3D volumetric segmentation of serial MRI data...
April 13, 2018: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29651796/oncological-impact-of-neoadjuvant-hormonal-therapy-on-permanent-iodine-125-seed-brachytherapy-in-patients-with-low-and-intermediate-risk-prostate-cancer
#3
Atsushi Takamoto, Ryuta Tanimoto, Kensuke Bekku, Motoo Araki, Takuya Sadahira, Koichiro Wada, Shin Ebara, Norihisa Katayama, Hiroyuki Yanai, Yasutomo Nasu
OBJECTIVES: To determine whether neoadjuvant hormonal therapy improves oncological outcomes of patients with localized prostate cancer treated with permanent brachytherapy. METHODS: Between January 2004 and November 2014, 564 patients underwent transperineal ultrasonography-guided permanent iodine-125 seed brachytherapy. We retrospectively analyzed low- or intermediate-risk prostate cancer based on the National Comprehensive Cancer Network guidelines. The clinical variables were evaluated for influence on biochemical recurrence-free survival, progression-free survival, cancer-specific survival and overall survival...
April 12, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/29651778/cost-consequence-analysis-alongside-a-randomised-controlled-trial-of-hospital-versus-telephone-follow-up-after-treatment-for-endometrial-cancer
#4
Padraig Dixon, Kinta Beaver, Susan Williamson, Chris Sutton, Pierre Martin-Hirsch, William Hollingworth
BACKGROUND: Regular outpatient follow-up programmes are usually offered to patients following treatment for gynaecological and other cancers. Despite the substantial resources involved in providing these programmes, there is evidence that routine follow-up programmes do not affect survival or the likelihood of detecting recurrence and may not meet patient needs. Alternative follow-up modalities may offer the same outcomes at lower cost. We examined the costs of using telephone-based routine follow-up of women treated for endometrial cancer undertaken by specialist gynaecology oncology nurses in comparison to routine hospital-based follow-up...
April 12, 2018: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/29651577/pathological-margin-clearance-and-survival-after-pancreaticoduodenectomy-in-a-us-and-european-pancreatic-center
#5
Stijn van Roessel, Gyulnara G Kasumova, Omidreza Tabatabaie, Sing Chau Ng, L Bengt van Rijssen, Joanne Verheij, Robert M Najarian, Thomas M van Gulik, Marc G Besselink, Olivier R Busch, Jennifer F Tseng
BACKGROUND: The optimal definition of a margin-negative resection and its exact prognostic significance on survival in resected pancreatic adenocarcinoma remains unknown. This study was designed to assess the relationship between pathological margin clearance, margin type, and survival. METHODS: Patients who underwent pancreaticoduodenectomy with curative intent at two academic institutions, in Amsterdam, the Netherlands, and Boston, Massachusetts, between 2000 and 2014 were retrospectively evaluated...
April 12, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29650858/-a-case-of-unresectable-advanced-gastric-cancer-treated-by-seven-courses-of-chemotherapy-with-docetaxel-cisplatin-and-s-1followed-by-conversion-surgery-achieved-five-year-relapse-free-survival
#6
Tetsushi Nakajima, Haruhiko Cho, Yoichiro Okubo, Kazuki Kano, Yukio Maezawa, Kousuke Ikeda, Takanobu Yamada, Takashi Ogata, Takaki Yoshikawa
The patient is a 51-year-old man.Upper gastrointestinal endoscopy revealed gigantic type 3 gastric cancer.Enhanced abdominal CT demonstrated a gigantic mass of 15×7 cm in the stomach, and a large number of peritoneal dissemination with moderate amount of ascites.The patient was diagnosed with cT4aN3bM1(peritoneal dissemination), Stage IV gastric cancer(JPN ver8)and was treated by chemotherapy with docetaxel(40mg/m / 2 day 1)plus cisplatin(60mg/m2 day 1)plus S-1(80mg/m2 day 1-14).After 7 courses of chemotherapy, peritoneal dissemination was disappeared...
April 2018: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29650751/fda-approval-summary-niraparib-for-the-maintenance-treatment-of-patients-with-recurrent-ovarian-cancer-in-response-to-platinum-based-chemotherapy
#7
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R Palmby, Soma Ghosh, Hisani N Horne, Eunice Y Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L Kelly, Kumar G Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B Goldberg, William F Pierce, Amna Ibrahim, Paul G Kluetz, Gideon M Blumenthal, Julia A Beaver, Richard Pazdur
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline BRCA mutation status (gBRCAm vs. non-gBRCAm). Progression-free survival (PFS) in each cohort was the primary endpoint...
April 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29650441/clinical-implications-of-tert-promoter-mutation-on-idh-mutation-and-mgmt-promoter-methylation-in-diffuse-gliomas
#8
Hyun Sik Kim, Mi Jung Kwon, Joon Ho Song, Eun Soo Kim, Ho Young Kim, Kyueng-Whan Min
IDH mutation and MGMT promoter methylation are reliable prognostic and predictive biomarkers in grade II-IV diffuse gliomas. Recurrent mutations in the promoter region of the telomerase reverse transcriptase (TERTp) gene have also been found in diffuse gliomas. However, the prognostic and predictive effects of TERTp mutation on IDH or MGMT status are largely unknown. IDH1/2 and TERTp mutations, as well as MGMT methylation statuses, were examined via peptide nucleic acid-mediated PCR clamping and MGMT methylation-specific PCR in 67 paraffinized tumor samples, respectively...
April 5, 2018: Pathology, Research and Practice
https://www.readbyqxmd.com/read/29650420/denosumab-treatment-of-inoperable-or-locally-advanced-giant-cell-tumor-of-bone-multicenter-analysis-outside-clinical-trial
#9
Piotr Rutkowski, Louie Gaston, Aneta Borkowska, Silvia Stacchiotti, Hans Gelderblom, Giacomo Giulio Baldi, Emanuela Palmerini, Paolo Casali, Alessandro Gronchi, Michael Parry, Domenico Andrea Campanacci, Guido Scoccianti, Michal Wagrodzki, Stefano Ferrari, Sander Dijkstra, Andrzej Pieńkowski, Robert Grimer
BACKGROUND: Giant cell tumor of bone (GCTB) is an osteolytic, locally aggressive, rarely metastazing bone tumor. This is a retrospective study evaluating a large series of GCTB patients treated with denosumab in routine practice in 6 European reference centers. METHODS: Patients with locally advanced, unresectable or metastatic GCTB, treated with denosumab outside clinical trials were eligible. Primary end-point was progression-free survival (PFS) for all patients; secondary end-points were: type of surgery, relapse rate and event-free survival for patients after preoperative denosumab + surgery...
March 31, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29650418/inflammatory-bowel-disease-drastically-affects-the-prognosis-of-patients-treated-for-peritoneal-metastases-with-combined-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-multicenter-study
#10
Nassim Hammoudi, Clarisse Eveno, Jérôme Lambert, Marianne Maillet, Olivier Glehen, Diane Goere, Nelson Lourenco, Matthieu Allez, Thomas Aparicio, Marc Pocard, Jean-Marc Gornet
BACKGROUND: Complete cytoreductive surgery (CCRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) is a validated treatment in selected patients with peritoneal metastases (PM) of intestinal origin. There is an increased risk of Colorectal Cancer (CRC) and Small Bowel Adenocarcinoma (SBA) in Inflammatory Bowel Disease (IBD). The feasibility and benefit of that surgical approach in IBD patients is unknown. METHODS: IBD patients with operated PM complicating CRC or SBA were extracted from a French national multicenter prospective database of patients who underwent surgery for PM in HIPEC expert centers from 1995 to 2016...
March 17, 2018: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/29650390/-18-f-fdg-pet-ct-parameters-to-predict-survival-and-recurrence-in-patients-with-locally-advanced-cervical-cancer-treated-with-chemoradiotherapy
#11
N Scher, J Castelli, A Depeursinge, J Bourhis, J O Prior, F G Herrera, M Ozsahin
PURPOSE: To identify predictive (18 F)-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)-based parameters for locoregional control, disease-free survival and overall survival, by testing different thresholds of metabolic tumor volume and total lesion glycolysis in patients with locally-advanced cervical cancer. PATIENTS AND METHODS: Thirty-seven patients treated with standard chemoirradiation underwent a pretreatment (18 F)-FDG-PET/CT...
April 9, 2018: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29649266/preoperative-dynamic-breast-magnetic-resonance-imaging-kinetic-features-using-computer-aided-diagnosis-association-with-survival-outcome-and-tumor-aggressiveness-in-patients-with-invasive-breast-cancer
#12
Sang Yu Nam, Eun Sook Ko, Yaeji Lim, Boo-Kyung Han, Eun Young Ko, Ji Soo Choi, Jeong Eon Lee
OBJECTIVES: To evaluate whether preoperative breast dynamic contrast-enhanced (DCE) magnetic resonance (MR) imaging kinetic features, assessed using computer-aided diagnosis (CAD), can predict survival outcome and tumor aggressiveness in patients with invasive breast cancer. MATERIALS AND METHODS: Between March and December 2011, 301 women who underwent preoperative DCE MR imaging for invasive breast cancer, with CAD data, were identified. All MR images were retrospectively evaluated using a commercially available CAD system...
2018: PloS One
https://www.readbyqxmd.com/read/29649089/prognostic-factors-of-patients-with-malignant-epithelioid-vascular-tumors-in-the-spine-retrospective-analysis-of-46-patients-in-a-single-center
#13
Kehan Xu, Yujie Liu, Bo Li, Jialin Li, Hao Zhang, Yuechao Zhao, Quan Huang, Haifeng Wei, Jianru Xiao
STUDY DESIGN: A retrospective study of 46 patients with malignant epithelioid vascular tumors (MEVT) in the spine was performed. OBJECTIVE: The purpose of this study was to illustrate the clinic characteristics of MEVT in the spine and to discuss prognostic factors by survival analysis. SUMMARY OF BACKGROUND DATE: MEVT in the spine is relatively uncommon, and there is little published information regarding this subject. Therefore, prognostic factors of this disease are still controversial...
April 11, 2018: Spine
https://www.readbyqxmd.com/read/29649052/recurrence-in-benign-paroxysmal-positional-vertigo-a-large-single-institution-study
#14
Alexander L Luryi, Juliana Lawrence, Dennis I Bojrab, Michael LaRouere, Seilesh Babu, John Zappia, Eric W Sargent, Eleanor Chan, Ilka Naumann, Robert S Hong, Christopher A Schutt
OBJECTIVE: To report rates of recurrence in benign paroxysmal positional vertigo (BPPV) and associated patient and disease factors. STUDY DESIGN: Retrospective chart review. SETTING: Single high-volume otology practice. PATIENTS: Patients diagnosed with BPPV from 2007 to 2016 with documented resolution of symptoms. INTERVENTION: Diagnostic and particle repositioning maneuvers for BPPV. MAIN OUTCOME MEASURES: BPPV recurrence, time to recurrence, and ear(s) affected at recurrence...
April 11, 2018: Otology & Neurotology
https://www.readbyqxmd.com/read/29645344/functional-and-oncologic-outcomes-of-open-laparoscopic-and-robotic-partial-nephrectomy-a-multicenter-comparative-matched-pair-analyses-with-a-median-5-years-follow-up
#15
Ki Don Chang, Ali Abdel Raheem, Kwang Hyun Kim, Cheol Kyu Oh, Sung Yul Park, Young Sik Kim, Won Sik Ham, Woong Kyu Han, Young Deuk Choi, Byung Ha Chung, Koon Ho Rha
PURPOSE: Data regarding the long-term oncologic and functional outcomes of robotic-assisted, laparoscopic, and open partial nephrectomy (RPN, LPN and OPN) is lacking. Our aim was to compare outcomes among RPN, LPN and OPN with a 5-year median follow-up. PATIENTS AND METHODS: We retrospectively analyzed 1308 patients who underwent PN (RPN, n=380; LPN, n=206; OPN, n=722) between 2006 and 2012 at four academic centers. We performed 1:1:1 propensity score matching adjustment based on confounding variables among groups and 366 patients (122 in each group) were included in the final analysis...
April 12, 2018: BJU International
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#16
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29644485/acceptance-and-compliance-of-ttfields-treatment-among-high-grade-glioma-patients
#17
Julia Onken, Franziska Staub-Bartelt, Peter Vajkoczy, Martin Misch
BACKGROUND: Tumor treating fields (TTFields) significantly prolong both progression-free and overall survival in patients with newly diagnosed glioblastoma (GBM). TTFields are delivered to the brain tumor via skin transducer arrays and should be applied for a minimum of 18 h per day (≥ 75% compliance). This may cause limited acceptance by patients because of obstacles in daily routine. So far, there are limited data on factors influencing therapy acceptance and compliance. METHODS: In this retrospective study, fourty-one patients with primary GBM or recurrent high grade glioma (rHGG) have been treated with TTFields in our department...
April 11, 2018: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/29644466/minimally-invasive-esophagectomy-attenuates-the-postoperative-inflammatory-response-and-improves-survival-compared-with-open-esophagectomy-in-patients-with-esophageal-cancer-a-propensity-score-matched-analysis
#18
Kotaro Yamashita, Masayuki Watanabe, Shinji Mine, Tasuku Toihata, Ian Fukudome, Akihiko Okamura, Masami Yuda, Masaru Hayami, Naoki Ishizuka, Yu Imamura
BACKGROUND: Minimally invasive esophagectomy (MIE) for patients with esophageal cancer has recently spread worldwide. However, whether MIE is less invasive has not yet been fully evaluated. METHODS: We retrospectively analyzed data from 551 patients who underwent curative esophagectomy for esophageal cancer from 2005 to 2014: 145 patients underwent minimally invasive esophagectomy (MIE) and 406 patients underwent open transthoracic esophagectomy (OE). We compared postoperative CRP levels with propensity score matching...
April 11, 2018: Surgical Endoscopy
https://www.readbyqxmd.com/read/29644427/-gender-specific-differences-of-the-early-postoperative-and-oncosurgical-long-term-outcome-in-rectal-cancer-data-obtained-in-a-prospective-multicenter-observational-study
#19
J Katzenstein, R Steinert, H Ptok, R Otto, I Gastinger, H Lippert, F Meyer
BACKGROUND: Gender-specific aspects have been increasingly considered in clinical medicine, also in oncological surgery. AIM: To analyze gender-specific differences of early postoperative and oncological outcomes after rectal cancer resection based on data obtained in a prospective multicenter observational study. PATIENTS AND METHODS: As part of the multicenter prospective observational study "Quality assurance in primary rectal cancer", data on tumor site, exogenic and endogenic risk factors, neoadjuvant treatment, surgical procedures, tumor stage, intraoperative and postoperative complications of patients with the histological diagnosis of rectal cancer were registered...
April 11, 2018: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
https://www.readbyqxmd.com/read/29644001/bag3-promotes-tumour-cell-proliferation-by-regulating-egfr-signal-transduction-pathways-in-triple-negative-breast-cancer
#20
Sarah Shields, Emer Conroy, Tony O'Grady, Alo McGoldrick, Kate Connor, Mark P Ward, Zivile Useckaite, Eugene Dempsey, Rebecca Reilly, Yue Fan, Anthony Chubb, David Gomez Matallanas, Elaine W Kay, Darran O'Connor, Amanda McCann, William M Gallagher, Judith A Coppinger
Triple-negative breast cancer (TNBC), is a heterogeneous disease characterised by absence of expression of the estrogen receptor (ER), progesterone receptor (PR) and lack of amplification of human epidermal growth factor receptor 2 (HER2). TNBC patients can exhibit poor prognosis and high recurrence stages despite early response to chemotherapy treatment. In this study, we identified a pro-survival signalling protein BCL2- associated athanogene 3 (BAG3) to be highly expressed in a subset of TNBC cell lines and tumour tissues...
March 20, 2018: Oncotarget
keyword
keyword
119234
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"